Overexpression of miR-127 Predicts Poor Prognosis and Contributes to the Progression of Papillary Thyroid Cancer by Targeting REPIN1

Abstract

Papillary thyroid cancer (PTC) is a major kind of thyroid cancer with increasing recurrence and metastasis. MiR-127 has been demonstrated to play roles in many cancers with dysregulation. However, the function of miR-127 is still unknown. This study aimed to explore a novel biomarker for the progression and prognosis of PTC. A set of 118 patients with PTC were collected from the Affiliated Hospital of Qingdao University. qRT-PCR was used to detect the expression of miR-127 in PTC tissues and cells. The association between miR-127 expression and the clinicopathological features of patients were evaluated by the χ² test, and the prognostic value of miR-127 was evaluated by Kaplan–Meier analysis and Cox regression analysis. The effect of miR-127 on cell proliferation, migration, and invasion of PTC was analyzed by CCK-8 and transwell assay. miR-127 was found to be upregulated in PTC tissues and cells correlated with the TNM stage and poor prognosis of PTC patients. MiR-127 and the TNM stage were considered as two independent prognostic indicators for PTC. Moreover, overexpression of miR-127 significantly enhanced cell proliferation, migration, and invasion of PTC by targeting REPIN1. miR-127 may be involved in the progression of PTC, which provides a new therapeutic strategy for PTC.

Key words

papillary thyroid cancer - miR-127 - prognosis - proliferation - migration - invasion

• References

• 1 Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: A period analysis. Lancet 2002; 360: 1131-1135
• 2 Pellegriti G, Scollo C, Lumera G. et al. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5 cm in diameter: study of 299 cases. J Clin Endocrinol Metab 2004; 89: 3713-3720
• 3 Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233
• 4 Volinia S, Calin GA, Liu CG. et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261
• 5 Cao XM. Role of miR-337-3p and its target Rap1A in modulating proliferation, invasion, migration and apoptosis of cervical cancer cells. Cancer Biomark 2019; 24: 257-267
• 6 Jin W, Han H, Liu D. Downregulation miR-539 is associated with poor prognosis of gastric cancer patients and aggressive progression of gastric cancer cells. Cancer Biomark 2019; 26: 183-191
• 7 Huang Y, Yu S, Cao S. et al. MicroRNA-222 promotes invasion and metastasis of papillary thyroid cancer through targeting protein phosphatase 2 regulatory subunit B alpha expression. Thyroid 2018; 28: 1162-1173
• 8 Sun J, Shi R, Zhao S. et al. E2F8, a direct target of miR-144, promotes papillary thyroid cancer progression via regulating cell cycle. J Exp Clin Cancer Res 2017; 36: 40
• 9 Yang F, Zhang H, Leng X. et al. miR-146b measurement in FNA to distinguish papillary thyroid cancer from benign thyroid masses. Br J Biomed Sci 2018; 75: 43-45
• 10 Rosignolo F, Memeo L, Monzani F. et al. MicroRNA-based molecular classification of papillary thyroid carcinoma. Int J Oncol 2017; 50: 1767-1777
• 11 Fan J, Du W, Zhang H. et al. Transcriptional downregulation of miR-127-3p by CTCF promotes prostate cancer bone metastasis by targeting PSMB5. FEBS Lett 2020; 594: 466-476
• 12 Shi X, Liu R, Basolo F. et al. Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab 2016; 101: 264-274
• 13 Iorio MV, Croce CM. MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol 2009; 27: 5848-5856
• 14 Kong YW, Ferland-McCollough D, Jackson TJ. et al. microRNAs in cancer management. Lancet Oncol 2012; 13: e249-e258
• 15 Fan X, Zhao Y. miR-451a inhibits cancer growth, epithelial-mesenchymal transition and induces apoptosis in papillary thyroid cancer by targeting PSMB8. J Cell Mol Med 2019; 23: 8067-8075
• 16 Yi T, Zhou X, Sang K. et al. MicroRNA-1270 modulates papillary thyroid cancer cell development by regulating SCAI. Biomed Pharmacother 2019; 109: 2357-2364
• 17 Wang Y, Zhang Q, Guo B. et al. miR-1231 is downregulated in prostate cancer with prognostic and functional implications. Oncol Res Treat 2020; 43: 78-86
• 18 Ahmadinejad F, Mowla SJ, Honardoost MA. et al. Lower expression of miR-218 in human breast cancer is associated with lymph node metastases, higher grades, and poorer prognosis. Tumour Biol 2017; 39: 1010428317698362
• 19 Qiu J, Zhang W, Zang C. et al. Identification of key genes and miRNAs markers of papillary thyroid cancer. Biol Res 2018; 51: 45
• 20 Shi L, Wang Y, Lu Z. et al. miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop. Oncogene 2017; 36: 1631-1643
• 21 You W, Wang Y, Zheng J. Plasma miR-127 and miR-218 might serve as potential biomarkers for cervical cancer. Reprod Sci 2015; 22: 1037-1041
• 22 Chang S, Sun L, Feng G. SP1-mediated long noncoding RNA POU3F3 accelerates the cervical cancer through miR-127-5p/FOXD1. Biomed Pharmacother 2019; 117: 109133
• 23 Lu M, Ju S, Shen X. et al. Combined detection of plasma miR-127-3p and HE4 improves the diagnostic efficacy of breast cancer. Cancer Biomark 2017; 18: 143-148
• 24 Fellenberg J, Lehner B, Saehr H. et al. Tumor suppressor function of miR-127-3p and miR-376a-3p in osteosarcoma cells. Cancers (Basel) 2019; 11: 2019
• 25 Wang Y, Kong D. Knockdown of lncRNA MEG3 inhibits viability, migration, and invasion and promotes apoptosis by sponging miR-127 in osteosarcoma cell. J Cell Biochem 2018; 119: 669-679
• 26 Wang Y, Lin Y. Hsa-mir-127 impairs survival of patients with glioma and promotes proliferation, migration and invasion of cancerous cells by modulating replication initiator 1. Neuroreport 2018; 29: 1166-1173
• 27 Wang L, Wang X, Jiang X. miR-127 suppresses gastric cancer cell migration and invasion via targeting Wnt7a. Oncol Lett 2019; 17: 3219-3226